financetom
Business
financetom
/
Business
/
Lifestance Health Group Insider Sold Shares Worth $332,143, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lifestance Health Group Insider Sold Shares Worth $332,143, According to a Recent SEC Filing
Jun 14, 2024 2:04 PM

04:42 PM EDT, 06/14/2024 (MT Newswires) -- Ryan Pardo, Chief Legal Officer and Secretary, on June 12, 2024, sold 61,508 shares in Lifestance Health Group ( LFST ) for $332,143. Following the Form 4 filing with the SEC, Pardo has control over a total of 3,297,959 shares of the company, with 746,439 shares held directly and 2,551,520 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1845257/000095017024073747/xslF345X03/ownership.xml

Price: 5.10, Change: -0.18, Percent Change: -3.41

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Iovance Biotherapeutics Q3 revenue up 13%, backs FY outlook
Iovance Biotherapeutics Q3 revenue up 13%, backs FY outlook
Nov 6, 2025
Overview * Iovance Biotherapeutics ( IOVA ) Q3 rev grows 13% to ~$68 mln, gross margin improves to 43% * Adjusted loss per share for Q3 beats analyst expectations * Company expects cash position to fund operations into Q2 2027 Outlook * Iovance reaffirms 2025 revenue guidance of $250 to $300 mln * Centralizing manufacturing in early 2026 to improve...
Viagra-maker Viatris beats quarterly estimates on strong demand for branded drugs
Viagra-maker Viatris beats quarterly estimates on strong demand for branded drugs
Nov 6, 2025
Nov 6 (Reuters) - Drugmaker Viatris beat third-quarter estimates for profit and revenue on Thursday, driven by strong demand for its branded drugs in China and emerging markets. The company also raised its 2025 forecasts, which financial chief Doretta Mistras said was primarily based on foreign exchange benefits and share repurchases. In August, the drugmaker had said that it expects...
Granite Construction Q3 Adjusted Earnings, Revenue Rise; 2025 Revenue Guidance Narrowed
Granite Construction Q3 Adjusted Earnings, Revenue Rise; 2025 Revenue Guidance Narrowed
Nov 6, 2025
08:12 AM EST, 11/06/2025 (MT Newswires) -- Granite Construction ( GVA ) reported Q3 adjusted earnings Thursday of $2.70 per diluted share, up from $2.05 a year earlier. Three analysts polled by FactSet expected $2.38. Revenue for the quarter ended Sept. 30 was $1.43 billion, compared with $1.28 billion a year earlier. Three analysts surveyed by FactSet expected $1.48 billion....
Sangamo Therapeutics Q3 revenue falls short, net loss widens
Sangamo Therapeutics Q3 revenue falls short, net loss widens
Nov 6, 2025
Overview * Sangamo Q3 2025 revenue misses analyst expectations, declining significantly from last year * Net loss for Q3 2025 was $34.9 mln, compared to net income last year * Company progresses Fabry disease program, preparing for BLA submission in 2026 Outlook * Sangamo expects BLA submission for Fabry disease in Q1 2026 * Company plans CTA submission for prion...
Copyright 2023-2026 - www.financetom.com All Rights Reserved